Automated Immunoassay Analyzers Market Grow 16.0% CAGR By 2029
The growth of automated immunoassay analyzers market in North America during the forecast period can be attributed to the growth of chronic disorders such as heart diseases. Furthermore, the widespread adoption of new medical devices in the healthcare sector across the North American subcontinent will further increase the preference for automated immunoassay analyzers in the region.
Explore More Insights@ https://www.alliedmarketresearch.com/request-toc-and-sample/11245
Immunoassay is a bioanalytical method used to determine the presence of a specific factor in the human body, which can be pathogens, antigens, hormones, antibodies, and enzymes. Furthermore, immunoassays are capable of quantifying compounds such as macromolecular molecules, biomarkers, low molecular weight drugs, and metabolites to indicate the diagnosis of diseases.
In September 2021, Thermo Fisher Scientific Inc., an analytical lab instrument manufacturing firm, introduced a fully automated analyzer designed for enzyme assay applications. Furthermore, the new fully automated enzyme analyzer can analyze a wide range of enzymes, offering many benefits to enzyme producers and enzyme users in food and beverages, chemicals, biopharmaceuticals, and fuel ethanol.
The increasing incidence of chronic and infectious diseases has fueled the growth of the automated immunoassay analyzer market across the globe. Prominent growth in the elderly population prone to infectious diseases has led to huge demand for diagnostic tests, which has embellished global industry trends. Innovations in current medical devices and growth in clinical applications in healthcare sector will increase the scope of automated immunoassay analyzers industry globally.
COVID-19 Impact Analysis
The widespread use of SARS-CoV-2 antigen rapid immunoassays for patients infected with COVID-19 has positively impacted the expansion of the global automated immunoassay analyzer market due to the COVID-19 pandemic. According to a clinical study by The Lancet, the lateral flow immunoassay provided accurate diagnosis and results of SARS-CoV-2 antibody tests in individuals screened for Covid-19 infection.
